Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 776 participants.
Also called NCT05168462
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 776 participants
- Registry
-
NCT05168462
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Recruiting
Technical summary
Registry record NCT05168462. Randomized; no masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2027-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
- Acronym
- NORSHOCK
- Condition
- Cardiogenic Shock
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Reduced noradrenaline use
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Record details
- Record id
cardio:ct-nct05168462- Content hash
fc977ddbc8cf9af5c4f7203db2ea525bc5d76aafac329c8eb4e11ff55f70342b